Advertisement

Rheumatology International

, Volume 39, Issue 6, pp 1037–1043 | Cite as

Serum visfatin levels in patients with axial spondyloarthritis and their relationship to disease activity and spinal radiographic damage: a cross-sectional study

  • Hana HulejováEmail author
  • Tereza Kropáčková
  • Kristýna Bubová
  • Olga Kryštůfková
  • Mária Filková
  • Heřman Mann
  • Šárka Forejtová
  • Michal Tomčík
  • Jiří Vencovský
  • Karel Pavelka
  • Ladislav Šenolt
Observational Research
  • 101 Downloads

Abstract

The purpose of this cross-sectional study was to assess the visfatin levels in patients with axial spondyloarthritis (axSpA) and to investigate the association between visfatin, disease activity and radiographic spinal damage. Serum visfatin levels were determined by enzyme-linked immunosorbent assay in 64 patients with axSpA (46 with radiographic axSpA (r-axSpA) and 18 with non-radiographic axSpA (nr-axSpA)) and 61 age-/sex-matched healthy individuals. Patients with r-axSpA were further divided into two subsets based on radiographic spinal damage using modified Stoke Ankylosing Spondylitis Spine Score (mSASSS = 0 and mSASSS ≥ 1). The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was used to assess disease activity. C-reactive protein (CRP) levels and human leukocyte antigen (HLA)-B27 were determined. Visfatin levels were significantly higher in patients with axSpA and in the subgroup of patients with r-axSpA than in healthy individuals (p = 0.010 and p = 0.005, respectively), with no difference between patients with r-axSpA and with nr-axSpA. In general, disease activity was high (mean BASDAI 5.01) and was moderately correlated with visfatin levels (r = 0.585; p = 0.011) in patients with nr-axSpA. Visfatin levels correlated with mSASSS (r = 0.281; p = 0.026) and were significantly higher in axSpA patients with mSASSS ≥ 1 than in those with mSASSS = 0 (p = 0.025). Our study showed that circulating visfatin levels are elevated in axSpA patients, may be associated with disease activity in early phase of the disease and with the degree of radiographic spinal involvement.

Keywords

Axial spondyloarthritis Visfatin Disease activity Radiographic damage 

Abbreviations

ASDAS

Ankylosing Spondylitis Disease Activity Score

axSpA

Axial spondyloarthritis

BASDAI

Bath Ankylosing Spondylitis Disease Activity Index

BMI

Body mass index

csDMARDs

Conventional synthetic disease-modifying anti-rheumatic drugs

bDMARDs

Biological disease-modifying anti-rheumatic drugs

CRP

C-reactive protein

ELISA

Enzyme-linked immunosorbent assay

HLA

Human leukocyte antigen

IQR

Interquartile range

MRI

Magnetic resonance imaging

mSASSS

Modified Stoke Ankylosing Spondylitis Spine Score

NAMPT

Nicotinamide phosphoribosyltransferase

nr-axSpA

Non-radiographic axial spondyloarthritis

NSAIDs

Non-steroidal anti-inflammatory drugs

PBEF

Pre-B cell colony-enhancing factor

r-axSpA

Radiographic axial spondyloarthritis

SIJ

Sacroiliac joints

Notes

Acknowledgements

This work was supported by the Ministry of Health of the Czech Republic project 17-33127A.

Author contributions

LŠ and JV were responsible for the study concept and design. HH performed ELISA tests. KB, MF, HM, ŠF, JV and LŠ were involved in enrolling the patients and made clinical assessments. HH, TL and OK carried out the statistical analysis. HH, TL and LŠ were responsible for data interpretation and manuscript preparation. MT, JV, KP and LŠ revised the manuscript critically for important intellectual content. All authors read and approved the final version of the manuscript.

Compliance with ethical standards

Ethical approval

All procedures performed in this study involving human participants were in accordance with the ethical standard of the local ethics committee of the Institute of Rheumatology in Prague, Czech Republic.

Informed consent

Written informed consent was obtained from all participants.

Conflict of interest

Hana Hulejová declares that she does not have competing interests. Tereza Kropáčková declares that she does not have competing interests. Kristýna Bubová declares that she does not have competing interests. Olga Kryštůfková declares that she does not have competing interests. Mária Filková declares that she does not have competing interests. Šárka Forejtová declares that she does not have competing interests. Heřman Mann declares that he does not have competing interests. Michal Tomčík declares that he does not have competing interests. Jiří Vencovský declares that he does not have competing interests. Karel Pavelka declares that he does not have competing interests. Ladislav Šenolt declares that he does not have competing interests.

Supplementary material

296_2019_4301_MOESM1_ESM.docx (179 kb)
Supplementary material 1 (DOCX 179 kb)

References

  1. 1.
    Sieper J, Poddubnyy D (2017) Axial spondyloarthritis. Lancet 390(10089):73–84CrossRefPubMedGoogle Scholar
  2. 2.
    Turina MC, Yeremenko N, van Gaalen F et al (2017) Serum inflammatory biomarkers fail to identify early axial spondyloarthritis: results from the SpondyloArthritis Caught Early (SPACE) cohort. RMD Open 3(1):e000319CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Poddubnyy D, Conrad K, Haibel H et al (2014) Elevated serum level of the vascular endothelial growth factor predicts radiographic spinal progression in patients with axial spondyloarthritis. Ann Rheum Dis 73(12):2137–2143CrossRefGoogle Scholar
  4. 4.
    Prajzlerova K, Grobelna K, Pavelka K, Senolt L, Filkova M (2016) An update on biomarkers in axial spondyloarthritis. Autoimmun Rev 15(6):501–509CrossRefPubMedGoogle Scholar
  5. 5.
    Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69(3):89–95CrossRefGoogle Scholar
  6. 6.
    Ouchi N, Parker JL, Lugus JJ, Walsh K (2011) Adipokines in inflammation and metabolic disease. Nat Rev Immunol 11(2):85–97. http://www.nature.com/articles/nri2921. Accessed 21 Jan 2011
  7. 7.
    Neumann E, Junker S, Schett G, Frommer K, Muller-Ladner U (2016) Adipokines in bone disease. Nat Rev Rheumatol 12(5):296–302. <Go to ISI>://WOS:000375276700006Google Scholar
  8. 8.
    Syrbe U, Callhoff J, Conrad K et al (2015) Serum adipokine levels in patients with ankylosing spondylitis and their relationship to clinical parameters and radiographic spinal progression. Arthritis Rheumatol 67(3):678–685CrossRefPubMedGoogle Scholar
  9. 9.
    Hartl A, Sieper J, Syrbe U et al (2017) Serum levels of leptin and high molecular weight adiponectin are inversely associated with radiographic spinal progression in patients with ankylosing spondylitis: results from the ENRADAS trial. Arthritis Res Ther 19(1):140.  https://doi.org/10.1186/s13075-017-1350-9 (Published online first 2017/06/18) CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I (1994) Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 14(2):1431–1437CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Moschen AR, Kaser A, Enrich B et al (2007) Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 178(3):1748–1758CrossRefPubMedGoogle Scholar
  12. 12.
    Luk T, Malam Z, Marshall JC (2008) Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity. J Leukoc Biol 83(4):804–816CrossRefGoogle Scholar
  13. 13.
    Xie H, Tang SY, Luo XH et al (2007) Insulin-like effects of visfatin on human osteoblasts. Calcif Tissue Int 80(3):201–210CrossRefPubMedGoogle Scholar
  14. 14.
    Moschen AR, Geiger S, Gerner R, Tilg H (2010) Pre-B cell colony enhancing factor/NAMPT/visfatin and its role in inflammation-related bone disease. Mutat Res 690(1–2):95–101CrossRefPubMedGoogle Scholar
  15. 15.
    Baek JM, Ahn SJ, Cheon YH, Lee MS, Oh J, Kim JY (2017) Nicotinamide phosphoribosyltransferase inhibits receptor activator of nuclear factor-kappaB ligand-induced osteoclast differentiation in vitro. Mol Med Rep 15(2):784–792CrossRefPubMedGoogle Scholar
  16. 16.
    Hulejova H, Levitova A, Kuklova M et al (2012) No effect of physiotherapy on the serum levels of adipocytokines in patients with ankylosing spondylitis. Clin Rheumatol 31(1):67–71.  https://doi.org/10.1007/s10067-011-1773-7. <Go to ISI>://WOS:000299768200009
  17. 17.
    Miranda-Filloy JA, Lopez-Mejias R, Genre F et al (2013) Leptin and visfatin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-alpha antagonist therapy. Clin Exp Rheumatol 31(4):538–545PubMedGoogle Scholar
  18. 18.
    Rudwaleit M, van der Heijde D, Landewe R et al (2009) The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68(6):777–783CrossRefPubMedGoogle Scholar
  19. 19.
    van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic-criteria for ankylosing-spondylitis—a proposal for modification of the New-York criteria. Arthritis Rheum 27(4):361–368. <Go to ISI>://WOS:A1984SN19400001Google Scholar
  20. 20.
    Brentano F, Schorr O, Ospelt C et al (2007) Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis Rheum 56(9):2829–2839CrossRefPubMedGoogle Scholar
  21. 21.
    Baraliakos X, Braun J (2015) Non-radiographic axial spondyloarthritis and ankylosing spondylitis: what are the similarities and differences? RMD Open.  https://doi.org/10.1136/rmdopen-2015-000053 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Huang J, Yin Z, Song G et al (2017) Discriminating value of calprotectin in disease activity and progression of nonradiographic axial spondyloarthritis and ankylosing spondylitis. Dis Markers 2017:7574147.  https://doi.org/10.1155/2017/7574147 (Published online first 2017/06/21) CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Baraliakos X (2014) The contribution of imaging in the diagnosis and treatment of axial spondyloarthritis. Eur J Clin Investig 45(1):81–86.  https://doi.org/10.1111/eci.12369 (Published online first 2014/11/08) CrossRefGoogle Scholar
  24. 24.
    Baraliakos X, Boehm H, Samir Barakat A et al (2018) OP0242 Fatty lesions detected on MRI scans in patients with ankylosing spondylitis are based on the deposition of fat in the vertebral bone marrow. Ann Rheum Dis 77(Suppl 2):170.  https://doi.org/10.1136/annrheumdis-2018-eular.7158 CrossRefGoogle Scholar
  25. 25.
    Esteghamati A, Alamdari A, Zandieh A et al (2011) Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity. Diabetes Res Clin Pract 91(2):154–158.  https://doi.org/10.1016/j.diabres.2010.11.003 (Epub 2010 Nov 30) CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Institute of RheumatologyPrague 2Czech Republic
  2. 2.Department of Rheumatology, First Faculty of MedicineCharles UniversityPragueCzech Republic

Personalised recommendations